Contineum assumed with an Overweight at Morgan Stanley

Morgan Stanley assumed coverage of Contineum (CTNM) with an Overweight rating. The firm believes PIPE-791 is competitive in idiopathic pulmonary fibrosis given its optimized pharmacokinetics and for PIPE-791 for primary progressive multiple sclerosis it believes Phase 1b topline results in Q2 can de-risk the Phase 2 study, the analyst tells investors.